The Food and Drug Administration Feb. 5 released an alert notifying patients of a safety concern using diabetes devices such as continuous glucose monitors, insulin pumps and automated insulin dosing systems that rely on a smartphone for delivering alerts. The agency said it received medical device reports in which users reported alerts were not being delivered or heard in situations where the users thought they configured the alerts to be delivered. Some instances may have contributed to serious harm, including severe hypoglycemia, severe hyperglycemia, diabetic ketoacidosis and death.   

The FDA issued recommendations for users and said it is working with diabetes-related medical device manufacturers to ensure that smartphone alert configurations are evaluated prior to use. It is also working with manufacturers to ensure settings for smartphones and mobile medical applications are continuously tested and that updates are communicated quickly and clearly to users.

Related News Articles

Headline
The AHA today submitted a letter to the Office of Science and Technology Policy in response to its request for information on regulatory reform for artificial…
Chairperson's File
Public
This week brings the fourth week of the federal government shutdown as Congress has yet to pass legislation to fund the government. This shutdown is a bit…
Headline
The AHA Oct. 23 recommended changes to the Centers for Medicare & Medicaid Services’ Wasteful and Inappropriate Services Reduction model to address…
Headline
Comments are due Oct. 27 to the Office of Science and Technology Policy on federal regulations that hinder artificial intelligence development, deployment or…
Headline
An AHA blog published today shares how HCA Healthcare in Nashville, Tenn., has been leveraging artificial intelligence to reduce risk and improve health…
Blog
Public
Cross-industry insights and new technology are helping HCA Healthcare reduce risk, improve outcomes and lead the future of high-reliability careFor Randy Fagin…